Case Reports in Genetics

Volume 2013 (2013), Article ID 279801, 3 pages

http://dx.doi.org/10.1155/2013/279801

Case Report

Detection of t(14;16)(q32;q22) and Monosomy 13 by FISH Analysis in a Patient with Multiple Myeloma Associated with Sjögren’s Syndrome: The First Case Report from India

Rupesh R. Sanap,¹ Arundhati S. Athalye,¹ Prochi F. Madon,¹ Boman N. Dhabhar,² Mahendra B. Sute,¹ Amit A. Mahabale,¹ Dhanashree J. Warang,¹ and Firuza R. Parikh¹

¹Department of Assisted Reproduction and Genetics, Jaslok Hospital and Research Centre, 15 Dr. G. Deshmukh Marg, Mumbai 400026, India

²Department of Oncology, Jaslok Hospital and Research Centre, 15 Dr. G. Deshmukh Marg, Mumbai 400026, India

Received 30 November 2012; Accepted 23 December 2012

Academic Editors: S.-C. Chae and G.-Q. Shen

Copyright © 2013 Rupesh R. Sanap et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Sjögren’s syndrome (SS) is a chronic slowly progressive autoimmune disorder characterized by symptoms of oral and ocular dryness, exocrine dysfunction, and lymphocytic infiltration of exocrine glands. Multiple myeloma (MM) is a bone-marrow-based malignant neoplasm of plasma cells associated with serum/urine monoclonal paraproteins and lytic skeletal lesions. There have been very few reported cases of MM, who had SS as the first presentation. We report a case of a woman diagnosed with Sjögren’s syndrome, who was later suspected to have multiple myeloma on serum protein electrophoresis. Fluorescence in situ hybridization (FISH) was carried out to check for deletions of loci 13q14.3, ATM, p53, and IGH (14q32) rearrangements on a bone marrow aspirate. Monosomy 13 was observed in 49% of cells, and a rearrangement at the IGH locus was seen in 42% of cells. To determine the partner chromosome associated with the IGH rearrangement, further FISH tests were set up for t(4;14)(p16;q32) followed by t(14;16)(q32;q22) on fresh slides. The test was negative for t(4;14) but positive for t(14;16) in 27% of cells. This confirmed the diagnosis of MM. We report the first case from India, having an association of Sjögren’s syndrome with multiple myeloma, which showed t(14;16) and monosomy 13 by FISH analysis.

1. Introduction

Sjögren’s syndrome (SS) is a chronic slowly progressive autoimmune disorder characterized by symptoms of oral and ocular dryness, exocrine dysfunction and lymphocytic infiltration of exocrine glands [1]. SS is predominantly the disease of middle-aged women, while myeloma is a disease of the elderly, with only 2% of cases occurring in patients <40 years of age.

Multiple myeloma (MM) is a cancer of the plasma cells which comprise 5% of the cells in bone marrow (BM). In a MM patient, this number can double, causing very serious health problems. MM is a bone-marrow-based malignant neoplasm associated with serum and/or urine monoclonal paraproteins and lytic skeletal lesions [2]. It accounts for around ten percent of all hematologic malignancies [3]. Myeloma cells are typically CD56, CD38, and CD138 positive and CD19 and CD45 negative. Previous studies using metaphase cytogenetics reported often complex numerical and structural chromosome abnormalities in 30%–40% of patients with MM [4]. The use of DNA specific probes and the technique of FISH enables us to study chromosomal abnormalities in interphase nuclei [5].

There have been very few reported cases of MM, which had SS as the first presentation [6–15]. To date, there is only 1 case report from India of a patient with SS and MM [16], which was not subjected to cytogenetic analysis to check for chromosomal abnormalities present in MM.

2. Case Report

A suspected case of MM was referred to us for chromosomal analysis. The female patient, aged 62, had a history of dry mouth since 2 years, significant weight loss (82 kg to 65 kg with a BMI of 33.8) in 6 months, excessive dry cough with bleeding, a pneumonia patch on X-ray, dry eyes, no tears, and loss of appetite. The total lymphocyte count was 4900/cu mm, RBC 3.11 mill/mm³, erythrocyte sedimentation rate 100 mm at 1st hour and 160 mm at 2nd hour, Hb 8.9 gm/dL, ANA 1 : 100 (weak positive), and RA factor ++. Multiple patchy areas of ground glass opacities in the subpleural region of apical/basal segments of both lower lobes, lingula, right middle lobe, and anterior segment of right upper lobe were seen. USG showed gall stones. Creatinine and SGPT were normal. The patient was diagnosed with Sjögren’s syndrome. She was on methylprednisolone, vitamins, and minerals.

Serum protein electrophoresis after 6 months showed total protein 10.9 gm/dL, globulin 9.16 gm/dL, hypoalbuminemia with decreased β2 region, gamma globulin 6.94 gm/dL, A/G ratio 0.36, and presence of M band in the gamma region (4.94 gm/dL). Hence multiple myeloma was suspected and the patient was referred to our laboratory for cytogenetic analysis.

FISH was set up on the whole bone marrow sample using Abbott (Vysis) CLL FISH panel with probes for loci 13q14.3, 13q34 (control), ATM, p53, and CEP 12 [17]. The IGH break-apart probe to check for rearrangements at the IGH locus (14q32) was used initially. The FISH results mainly showed monosomy 13 in 49% and rearrangement at the IGH locus in 42% cells. Subsequently, the patient was tested for t(4;14)(p16;q32) which was negative. A further test was carried out to check for rearrangement of IGH with MAF (16q22-23). This showed the translocation t(14;16)(q32;q22) in 27% cells (Figure 1).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

Figure 1: FISH images of normal and abnormal cells using various probes. (a) A normal cell showing 2 green (G), 2 orange (O) and 2 aqua (A) signals for chromosome 12 and loci 13q14.3 and 13q34 on chromosome 13, respectively, using Vysis CLL probe set for CEP12, 13q14.3 and 13q34. (b) A cell showing 2G1O1A signal pattern indicating monosomy 13 using Vysis CLL probe set for CEP12, 13q14.3, and 13q34. (c) Normal cell showing 2 fusion (F) signals for IGH locus (14q32) using Vysis IGH break-apart rearrangement probe. (d) A cell showing 1G1O1F signal pattern indicating IGH rearrangement at 14q32 using Vysis IGH break-apart rearrangement probe. (e) A normal cell showing 2 green and 2 orange signals for chromosomes 11 and 17, respectively, using Vysis CLL probe set for 11q23 (ATM) and 17p13.1 (p53). (f) A normal cell showing 2 orange and 2 green signals for chromosomes 4 and 14, respectively, using Vysis LSI IGH-FGFR3 dual colour dual fusion translocation probe. (g) A normal cell showing 2 green and 2 orange signals for chromosomes 14 and 16, respectively, using Vysis LSI IGH-MAF dual colour dual fusion translocation probe. (h) A cell showing 1G1O2F signal pattern indicating IGH-MAF fusion for t(14;16) using Vysis LSI IGH-MAF dual colour dual fusion translocation probe.

3. Discussion

Based on the revised international classification criteria for SS [18], this patient satisfied the diagnostic criteria of SS. Serum electrophoresis showed the presence of M band and more than 10% plasma cells on bone marrow aspiration. The diagnosis of MM was further supported by the presence of t(14;16) and monosomy 13 by FISH on BM. Monosomy 13 was one of the first recurrent chromosomal abnormalities found in MM [19]. Up to one-third of MM may emerge from preexisting monoclonal gammopathy of undetermined significance (MGUS), and monosomy 13 has been correlated with the transformation of MGUS to overt MM [20]. The cryptic translocation t(14;16)(q32;q22) was first detected by multicolour spectral karyotyping (SKY) as a nonrandom abnormality in MM [21].

According to the current risk stratification criteria for MM, t(14;16), t(14;20) and deletion 17p are stratified as high risk myeloma, whereas monosomy 13 or deletion 13, t(4;14) and hypodiploidy are considered to have intermediate risk disease [18]. All others are considered to have standard risk myeloma [3].

Our patient is currently on Bortezomib and is responding well. Her recent Hb is 10.5 gm/dL and her weight has increased to 70 kg. This is the first case report from India, describing an association of Sjögren’s syndrome with multiple myeloma showing t(14;16)(q32;q22) and deletion 13q14.3 by FISH analysis.

References

C. Fox Philip, Salivary Gland Disorders, Burket’s Oral Medicine, Greenberg-Glick-Ship, 11th edition, 2008.

T. M. Grogan, B. Van Camp, R. A. Kyle, et al., “Plasma cell neoplasms,” in Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, E. S. Jaffe, N. L. Harris, and H. Stein, Eds., World Health Organization Classification of Tumours, pp. 142–156, IARC Press, Lyon, France, 2001.

S. V. Rajkumar, “Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management,” American Journal of Hematology, vol. 87, no. 1, pp. 78–88, 2012.

H. J. Weh, K. Gutensohn, J. Selbach et al., “Karyotype in multiple myeloma and plasma cell leukaemia,” European Journal of Cancer Part A, vol. 29, no. 9, pp. 1269–1273, 1993.

D. Pinkel, T. Straume, and J. W. Gray, “Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 9, pp. 2934–2938, 1986.

Y. Akashi, N. Yoshizawa, T. Kubota et al., “Primary biliary cirrhosis complicated with Sjogren syndrome and multiple myeloma. A case report,” Nephron, vol. 73, no. 4, pp. 730–732, 1996.

I. Tazi, M. Rachid, and S. Benchekroun, “Sjögren's syndrome associated with multiple myeloma,” Singapore Medical Journal, vol. 49, no. 8, pp. e215–e216, 2008.

H. Kaneko, Y. Ohkawara, K. Taniguchi et al., “Simultaneous complication of multiple myeloma with Sjögren syndrome,” Asian Pacific Journal of Allergy and Immunology, vol. 24, no. 4, pp. 245–248, 2006.

M. A. Shearn, H. M. Moutsopoulos, S. Sawada, and C. Gak, “Letter: Sjögren's syndrome with light chain myeloma,” Western Journal of Medicine, vol. 123, no. 6, pp. 496–497, 1975.

H. Fujii, S. Seki, and T. Kanoh, “A case of multiple myeloma with initial symptoms of xerostomia and keratoconjunctivitis sicca,” Nippon Naika Gakkai Zasshi, vol. 72, pp. 1749–1755, 1983.

T. Ota, A. Wake, S. Eto, and T. Kobayashi, “Sjögren’s syndrome terminating with multiple myeloma,” Scandinavian Journal of Rheumatology, vol. 24, pp. 316–318, 1995.

A. Rodriguez-Cuartero and A. Salas-Galan, “Sjögren’s syndrome and multiple myeloma,” European Journal of Cancer, vol. 33, pp. 167–168, 19971997.

Y. Harada, Y. Egi, Y. Honda, T. Shirota, and T. Hayashi, “Multiple myeloma with Sweet disease developing from monoclonal gammopathy of undetermined significance and Sjögren syndrome,” The Japanese Journal of Clinical Hematology, vol. 42, no. 12, pp. 1176–1180, 2001.

E. Terpos, M. K. Angelopoulou, E. Variami, J. C. Meletis, and G. Vaiopoulos, “Sjogrens syndrome associated with multiple myeloma,” Annals of Hematology, vol. 79, no. 8, pp. 449–451, 2000.

S. A. Fadilah and S. K. Cheong, “Multiple myeloma presenting as Sjogren's syndrome,” American Journal of Hematology, vol. 61, pp. 217–218, 1999.

U. P. Kulkarni, Y. A. Gokhale, P. M. Raut, and R. R. Dargad, “An unusal cause for sicca syndrome,” Journal of Postgraduate Medicine, vol. 57, no. 2, pp. 129–130, 2011.

http://www.abbottmolecular.com/products/oncology/fish

C. Vitali, S. Bombardieri, R. Jonsson, H. M. Moutsopoulos, E. L. Alexander, and S. E. Carsons, “Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group,” Annals of the Rheumatic Diseases, vol. 61, pp. 554–558, 2002.

P. J. Ho, “Chromosomal and genetic abnormalities in myeloma,” Clinical & Laboratory Haematology, vol. 24, pp. 259–269, 2002.

H. Avet-Loiseau, J. Y. Li, N. Morineau et al., “Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma,” Blood, vol. 94, no. 8, pp. 2583–2589, 1999.

J. R. Sawyer, J. L. Lukacs, N. Munshi et al., “Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping,” Blood, vol. 92, no. 11, pp. 4269–4278, 1998.